“Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report”, Mediterr J Hematol Infect Dis, vol. 14, no. 1, p. e2022043, Apr. 2022, doi: 10.4084/MJHID.2022.043.